Efficacy of Xuebijing Combined with Ulinastatin in the Treatment of Traumatic Sepsis and Effects on Inflammatory Factors and Immune Function in Patients

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 May 20

PMID 35592125

Authors

Yuanchao Su

Yunliang Zhang

Hongsheng Yuan

Chuan Shen

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the efficacy of xuebijing combined with ulinastatin in the treatment of traumatic sepsis and analyze the effects on inflammatory factors and immune function of patients.

Methods: 182 patients with traumatic sepsis were selected from June 2017 to September 2021 in our hospital. The patients were divided into the control group and the observation group. Patients in both groups were given routine treatments such as initial resuscitation, blood transfusion, monitoring of lactic acid to guide fluid replacement, early control of infection source, selection of appropriate antibiotics, correction of acidosis, treatment of primary disease, prevention of hypothermia and stress ulcer, application of vasoactive drugs, application of glucocorticoid and nutritional support. The control group was treated with Xuebijing injection on the basis of routine treatment, and the observation group was given Xuebijing injection combined with ulinastatin treatment on the basis of routine treatment. The APACHE II score was applied to evaluate the patients before and after treatment, and the routine blood indicators, inflammatory factor indicators, immune function indicators and liver function indicators were tested.

Results: After the treatment, the APACHE II score of the observation group was (10.35 ± 3.04) lower than that of the control group (15.93 ± 4.52) ( < 0.05). After treatment, the WBC and neutrophils in the observation group (15.19 ± 2.91) and (0.65 ± 0.04) were lower than those in the control group (16.42 ± 3.44) and (0.79 ± 0.05), and the PLT(162.85 ± 43.92) was higher than that in the control group (122.68 ± 36.89) ( < 0.05). After treatment, the levels of serum PCT, IL-6, TNF-α in the observation group were (11.38 ± 3.05), (10.74 ± 3.82) and (9.82 ± 2.35) lower than those in the control groups (17.34 ± 3.29), (15.28 ± 4.05) and (13.24 ± 3.06) ( < 0.05). After treatment, the levels of CD3+, CD4+, CD8+, CD4+/CD8+ in the observation group were (50.64 ± 4.98), (40.56 ± 4.82), (27.22 ± 3.29), (1.49 ± 0.24) higher than those in the control groups (46.08 ± 4.75), (34.69 ± 4.08), (25.14 ± 3.18), (1.38 ± 0.19) ( < 0.05). After treatment, the levels of TBIL and AST in the observation group were (12.35 ± 3.82), (25.66 ± 4.49) lower than those in the control group (18.43 ± 4.06), (34.58 ± 5.06) ( < 0.05).

Conclusion: Xubijing combined with ulinastatin has a good effect in the treatment of patients with traumatic sepsis, which can effectively improve the condition, reduce the body's inflammatory response, and promote the recovery of patients' immune function and liver function.

Citing Articles

The Effect of Hybrid Blood Purification Combined with Ulinastatin for the Treatment of Severe Sepsis on APACHE II Score and Levels of miR-146a and miR-155.

Wang K, Zhu J, Gao W, Guo W, Guo Y Int J Gen Med. 2024; 17:5897-5905.

PMID: 39678685 PMC: 11645247. DOI: 10.2147/IJGM.S491193.

Effect of Oxygen-Glucose Deprivation of Microglia-Derived Exosomes on Hippocampal Neurons: A Study on miR-124 and Inflammatory Cytokines.

Zhu Y, Zhao X, Liu R, Yang D, Ge G J Mol Histol. 2024; 55(3):349-357.

PMID: 38598045 DOI: 10.1007/s10735-024-10193-6.

Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial.

Tao Y, Han Q, Jiao W, Yang L, Wang F, Xue S World J Clin Cases. 2023; 11(31):7583-7592.

PMID: 38078125 PMC: 10698442. DOI: 10.12998/wjcc.v11.i31.7583.

Efficacy of Fangfeng Tongsheng Granule Combined with Levocetirizine in the Treatment of Chronic Urticaria and Its Effect on Serum Complement, IL-4, IgE, and IFN- Levels in Patients.

Xu D, Li Z, Wang Y Evid Based Complement Alternat Med. 2022; 2022:4012416.

PMID: 36212973 PMC: 9546688. DOI: 10.1155/2022/4012416.

References

Eguia E, Bunn C, Kulshrestha S, Markossian T, Durazo-Arvizu R, Baker M . Trends, Cost, and Mortality From Sepsis After Trauma in the United States: An Evaluation of the National Inpatient Sample of Hospitalizations, 2012-2016. Crit Care Med. 2020; 48(9):1296-1303. PMC: 7872079. DOI: 10.1097/CCM.0000000000004451. View

Cardozo Junior L, Silva R . Sepsis in intensive care unit patients with traumatic brain injury: factors associated with higher mortality. Rev Bras Ter Intensiva. 2014; 26(2):148-54. PMC: 4103941. DOI: 10.5935/0103-507x.20140022. View

Wang J, Zhou J, Bai S . Combination of Glutamine and Ulinastatin Treatments Greatly Improves Sepsis Outcomes. J Inflamm Res. 2020; 13:109-115. PMC: 7037133. DOI: 10.2147/JIR.S234122. View

Gawlytta R, Brunkhorst F, Niemeyer H, Boettche M, Knaevelsrud C, Rosendahl J . Dyadic post-traumatic stress after intensive care: Case report of a sepsis patient and his wife. Intensive Crit Care Nurs. 2020; 58:102806. DOI: 10.1016/j.iccn.2020.102806. View

Chen S, Wei I, Sang Y, Tang F . ICU nurses' knowledge of, and attitudes towards, the APACHE II scoring system. J Clin Nurs. 2004; 13(3):287-96. DOI: 10.1046/j.1365-2702.2003.00864.x. View

Xiao S, Luo L, Liu X, Zhou Y, Liu H, Huang Z . Curative efficacy and safety of traditional Chinese medicine xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: A meta-analysis. Medicine (Baltimore). 2018; 97(23):e10971. PMC: 5999488. DOI: 10.1097/MD.0000000000010971. View

Horn D, Mindrinos M, Anderson K, Krishnakumar S, Wang C, Li M . HLA-A Locus is Associated With Sepsis and Septic Shock After Traumatic Injury. Ann Surg. 2020; 275(1):203-207. PMC: 10060028. DOI: 10.1097/SLA.0000000000003932. View

Meng F, Du C, Zhang Y, Wang S, Zhou Q, Wu L . Protective effect of rhubarb combined with ulinastatin for patients with sepsis. Medicine (Baltimore). 2020; 99(7):e18895. PMC: 7035124. DOI: 10.1097/MD.0000000000018895. View

Gan L, Hu C, Deng Z, Lu H, Sun J, Peng G . Rs1982809 is a functional biomarker for the prognosis of severe post-traumatic sepsis and MODs. Exp Biol Med (Maywood). 2019; 244(16):1438-1445. PMC: 6900703. DOI: 10.1177/1535370219880490. View

10.

Venturi L, Miranda M, Selmi V, Vitali L, Tani A, Margheri M . Systemic sepsis exacerbates mild post-traumatic brain injury in the rat. J Neurotrauma. 2009; 26(9):1547-56. DOI: 10.1089/neu.2008.0723. View

11.

Li C, Wang P, Li M, Zheng R, Chen S, Liu S . The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms. J Ethnopharmacol. 2020; 265:113301. DOI: 10.1016/j.jep.2020.113301. View

12.

Tian S, Qin D, Ye Y, Yang H, Chen S, Liu T . Scientific Evidence of Xuebijing Injection in the Treatment of Sepsis. Evid Based Complement Alternat Med. 2021; 2021:6879278. PMC: 8560249. DOI: 10.1155/2021/6879278. View

13.

Pandya A, Chaput K, Schertzer A, Moser D, Guilfoyle J, MacGillivray S . Risk of Infection and Sepsis in Pediatric Patients with Traumatic Brain Injury Admitted to Hospital Following Major Trauma. Sci Rep. 2018; 8(1):9798. PMC: 6023879. DOI: 10.1038/s41598-018-28189-0. View

14.

Shi H, Hong Y, Qian J, Cai X, Chen S . Xuebijing in the treatment of patients with sepsis. Am J Emerg Med. 2016; 35(2):285-291. DOI: 10.1016/j.ajem.2016.11.007. View

15.

Tseng C, Chen T, Wu M, Chan M, Shih M, Tu Y . Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses. Crit Care. 2020; 24(1):693. PMC: 7734863. DOI: 10.1186/s13054-020-03419-y. View

16.

Chen J, Xuan J, Gu Y, Shi K, Xie J, Chen J . Celastrol reduces IL-1β induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo. Biomed Pharmacother. 2017; 91:208-219. DOI: 10.1016/j.biopha.2017.04.093. View

17.

Wang H, Liu B, Tang Y, Chang P, Yao L, Huang B . Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019; 10:1370. PMC: 6893897. DOI: 10.3389/fphar.2019.01370. View

18.

Tan D, Wiseman T, Betihavas V, Rolls K . Patient, provider, and system factors that contribute to health care-associated infection and sepsis development in patients after a traumatic injury: An integrative review. Aust Crit Care. 2020; 34(3):269-277. DOI: 10.1016/j.aucc.2020.08.004. View

19.

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(2):580-637. DOI: 10.1097/CCM.0b013e31827e83af. View

20.

Gupta D, Sharma A, Soni K, Kazim S, Bhoi S, Rao D . Changes in the behaviour of monocyte subsets in acute post-traumatic sepsis patients. Mol Immunol. 2021; 136:65-72. DOI: 10.1016/j.molimm.2021.04.005. View